For the quarter ended March 2026, Mirum Pharmaceuticals, Inc. (MIRM) reported revenue of $159.88 million, up 43.3% over the same period last year. EPS came in at -$0.39, compared to -$0.30 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $148.04 million, representing a surprise of +8%. The company delivered an EPS surprise of +3.47%, with the consensus EPS estimate being -$0.40.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Mirum Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product Sales- Livmarli: $113.8 million compared to the $104.83 million average estimate based on three analysts. Total product sales, net: $159.88 million versus the three-analyst average estimate of $146.86 million. Product Sales- Bile Acid Medicines: $46.08 million compared to the $42.06 million average estimate based on three analysts.View all Key Company Metrics for Mirum Pharmaceuticals here>>>
Shares of Mirum Pharmaceuticals have returned +10.6% over the past month versus the Zacks S&P 500 composite's +10.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Mirum Pharmaceuticals, Inc. (MIRM): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).